The role of genes in the development of mullerian anomalies: Where are we today?

Obstetrical and Gynecological Survey

Volumn 64, Issue 11, 2009, Pages 760-768

  Christopoulos, Panagiotis ^a   Gazouli, Maria ^a   Fotopoulou, Georgia ^a   Creatsas, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; HEPATOCYTE NUCLEAR FACTOR 1BETA; LIM PROTEIN; MUELLERIAN INHIBITING FACTOR; PROTEIN P63; TRANSCRIPTION FACTOR EMX2; TRANSCRIPTION FACTOR PAX2; WNT PROTEIN;

EMBRYO DEVELOPMENT; FEMALE GENITAL TRACT MALFORMATION; GENE; HOX GENE; HUMAN; LIVE BIRTH; MOLECULAR GENETICS; MUELLERIAN DUCT; NONHUMAN; PATHOGENESIS; REVIEW; ROKITANSKY SYNDROME; SEX DIFFERENTIATION;

AMENORRHEA; ANIMALS; ANTI-MULLERIAN HORMONE; FEMALE; GENITALIA, FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MICE; MULLERIAN DUCTS; MUTATION; PAX2 TRANSCRIPTION FACTOR; PHENOTYPE; PROTO-ONCOGENE PROTEINS; WNT PROTEINS;

EID: 70449368720     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3181bea203     Document Type: Review

References (78)

1. Kobayashi A, Behringer RR. Developmental genetics of the female reproductive tract in mammals. Nat Rev Genet 2003; 4:969-980.
2. Caroll TJ, Park J, Hayashi S, et al. Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. Dev Cell 2005;9:283-292.
3. Kobayashi A, Shawlot W, Kania A, et al. Requirement of Lim1 for female reproductive tract development. Development 2004;131:539-549.
4. Rey R. Anti-Mullerian hormone in disorders of sex determination and differentiation. Arq Bras Endocrinol Metabol 2005;49: 26-36.
5. Zhan Y, Fujino A, MacLaughlin DT, et al. Mullerian inhibiting substance regulates its receptors/SMAD signalling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression. Development 2006;133: 2359-2369.
6. Roberts LM, Visser JA, Ingraham HA. Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development. Development 2002;129:1487-1496.
7. Massé J, Watrin T, Laurent A, et al. The developing female genital tract: from genetics to epigenetics. Int J Dev Biol 2009;53:411-424.
8. Miller C, Pavlovo A, Sassoon DA. Differential expression patterns of Wnt genes in the murine female reproductive tract during development and the estrous cycle. Mech Dev 1998; 76:91-99.
9. Deutscher E, Hung-Chang Yao H. Essential roles of mesenchyme-derived beta-catenin in mouse Müllerian duct morphogenesis. Dev Biol 2007;307:227-236.
10. Biason-Lauber A, Konrad D. Wnt4 and sex development. Sex Dev 2008;2:210-218.
11. Vainio S, Heikkila M, Kispert A, et al. Female development in mammals is regulated by Wnt4 signaling. Nature 1999;397: 405-409.
12. Jeays-Ward K, Daudonneau M, Swan A. Wnt4 is required for proper male as well female sexual development. Dev Biol 2004;276:431-440.
13. Sultan C, Biason-Lauber A, Philibert P. Mayer-Rokitansky-Kuster-Hauser syndrome: recent clinical and genetic findings. Gynecol Endocrinol 2009;25:8-11.
14. Philibert P, Biason-Lauber A, Rouzier R, et al. Identification and functional analysis of a new Wnt4 gene mutation among 28 adolescent girls with primary amenorrhea and mü llerian duct abnormalities: a French collaborative study. J Clin En-docrinol Metab 2008;93:895-900.
15. Biason-Lauber A, De Filippo G, Konrad D, et al. Wnt4 deficiency-a clinical phenotype distinct from the classic MRKH syndrome: a case report. Hum Reprod 2007;22: 224-229.
16. Mericskay M, Kitajewski J, Sassoon D. Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development 2004;131:2061-2072.
17. Parr BA, McMahon AP. Sexually dimorphic development of the mammalian reproductive tract requires Wnt7a. Nature 1998;395:707-710.
18. Miller C, Sassoon DA. Wnt7a maintains appropriate uterine patterning during the development of the mouse female reproductive tract. Development 1998;125:3201-3211.
19. Carta L, Sassoon D. Wnt7a is a suppressor of cell death in the female reproductive tract and is required for postnatal and estrogen-mediated growth. Biol Reprod 2004;71:444-454.
20. Ma R, Sassoon DA. PCBs exert an estrogenic effect through repression of the Wnt7a signaling pathway in the female reproductive tract. Environ Health Perspect 2006;114:898-904.
21. Qian J, Jiang Z, Li M, et al. Mouse Wnt9b transforming activity, tissue-specific expression, and evolution. Genomics 2003; 81:34-46.
22. Kirikoshi H, Vainio S, McMahon AP. Molecular cloning and characterization of WNT14B, a novel member of the WNT gene family. Int J Oncol 2001;19:947-952.
23. Bergstein I, Eisenberg LM, Bhalerao J, et al. Isolation of two novel WNT genes, WNT14 and WNT15, one of which (wNT15) is closely linked to WNT3 on human chromosome 17q21. Genomics 1997;46:450-458.
24. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653: 1-24.
25. Bejsovec A. Wnt pathway activation: new relations and locations. Cell 2005;120:11-14.
26. Bach I. The LIM domain: regulation by association. Mech Dev 2000;91:5-17.
27. Hobert O, Westphal H. Functions of LIM-homeobox genes. Trends Genet 2000;16:75-83.
28. Tsang TE, Shawlot W, Kinder SJ, et al. Lim1 activity is required for intermediate mesoderm differentiation in the mouse embryo. Dev Biol 2000;223:77-90.
29. Birk OS, Casiano DE, Wassif CA, et al. The LIM homeobox gene Lhx9 is essential for mouse gonad formation. Nature 2000;403:909-913.
30. Bouchard M, Souabni A, Mandler M, et al. Nephric lineage specification by Pax2 and Pax8. Genes Dev 2002;16:2958-2970.
31. Shawlot W, Behringer RR. Requirement for Lim1 in head-organizer function. Nature 1995;374:425-430.
32. Hukriede NA, Tsang TE, Habas R, et al. Conserved requirement of Lim1 function for cell movements during gastrulation. Dev Cell 2003;4:83-94.
33. Tam PP, Rossant J. Mouse embryonic chimeras: tools for studying mammalian development. Development 2003;130: 6155-6163.
34. Torres M, Gomez-Pardo E, Dressler GR, et al. Pax-2 controls multiple steps of urogenital development. Development 1995; 121:4057-4065.
35. Du H, Taylor HS. Molecular regulation of Mullerian development by Hox genes. Ann NY Acad Sci 2004;1034:152-165.
36. Bateson W. Materials for the Study of Variation: Treated With Special Regard to Discontinuity in the Origin of Species. Ithaca, New York: Cornell University Press, Mann Library; 1894.
37. Zhao I, Potter SS. Functional comparison of the Hoxa4, Hoxa10 and Hoxa11 homeoboxes. Dev Biol 2002;244:21-36.
38. Goodman FR. Limb malformations and the human Hox genes. Am J Med Genet 2002;112:256-265.
39. Lalwani S, Wu HH, Reindollar RH, et al. Hoxa10 mutations in congenital absence of uterus and vagina. Fertil Steril 2008;89: 325-330.
40. Taylor HS. The role of Hox genes in the development and function of the female reproductive tract. Semin Reprod Med 2000;18:81-89.
41. Zhao Y, Potter SS. Functional specificity of the Hoxa13 ho-meobox. Development 2001;128:3197-3207.
42. Post LC, Margulies EH, Kuo A, et al. Severe limb defects in Hypodactyly mice result from the expression of a novel. Mutant Hoxa13 protein. Dev Biol 2000;217:290-300.
43. Goodman FR, Bacchelli C, Brady AF, et al. Novel Hoxa13 mutations and the phenotypic spectrum of hand-foot-genital syndrome. Am J Hum Genet 2000;67:197-202.
44. Cermic D, Karaca M, Taylor HS. Hox10 expression is repressed by progesterone in the myometrium: differential tissue specific regulation of Hox gene expression in the reproductive tract. J Clin Endocrinol Metab 2001;86:3387-3392.
45. Akbas GE, Song J, Taylor HS. A Hoxa10 estrogen response element (ERE) is differentially regulated by 17 beta-estradiol and diethylstilbestrol (DES). J Mol Biol 2004;340:1013-1023.
46. Suzuki A, Urushitani H, Sato T, et al. Gene expression change in the Mü llerian duct of the mouse fetus exposed to diethyl-stilbestrol in utero. Exp Biol Med (Maywood) 2007;232:503-514.
47. Conlon RA. Retinoic acid and pattern formation in vertebrates. Trends Genet 1995;11:314-319.
48. Daftary GS, Troy PJ, Bagot CN, et al. Direct regulation of beta3-integrin subunit gene expression by Hoxa10 in endo-metrial cells. Mol Endocrinol 2002;16:571-579.
49. Guerrier D, Mouchel T, Pasquier L, et al. The Mayer-Rokitansky-Kuster- Hauser syndrome (congenital absence of uterus and vagina)-phenotypic manifestations and genetic approaches. J Negat Results Biomed 2006;5:1.
50. Miyamoto N, Yoshida M, Kuratani S, et al. Defects of urogen-ital development in mice lacking Emx2. Development 1997; 124:1653-1664.
51. Troy PJ, Daftary GS, Bagot CN, et al. Transcriptional repression of peri-implantation EMX2 expression in mammalian reproduction by Hoxa10. Mol Cell Biol 2003;23:1-13.
52. Noonan FC, Goodfellow PJ, Staloch LJ, et al. Antisense transcripts at the EMX2 locus in human and mouse. Genomics 2003;81:58-66.
53. Daftary GS, Taylor HS. EMX2 gene expression in the female reproductive tract and aberrant expression in the endome-trium of the patients with endometriosis. J Clin Endocrinol Metab 2004;89:2390-2396.
54. Lindner TH, Njolstad PR, Horikawa Y, et al. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. Hum Mol Genet 1999;8:2001-2008.
55. Ince TA, Cviko AP, Quade BJ, et al. P63 coordinates anogeni-tal modeling and epithelial cell differentiation in the developing female urogenital tract. Am J Pathol 2002;161:1111-1117
56. Jarmiń ska-Jackowiak T, Warenik-Szymankiewicz A, Trzeciak WH. Anti-Mullerian hormone: structure and role in sexual differentiation. Ginekol Pol 1995;66:51-58.
57. Josso N, Belville C, di Clemente N, et al. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum Reprod Update 2005;11:351-356.
58. Clarke TR, Hoshiya Y, Yi SE, et al. Mullerian inhibiting substance signalling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Mol Endocrinol 2001;15:946-959.
59. Du X, Hublitz P, Gunther T, et al. The LiM-only coactivator FHL2 modulates WT1 transcriptional activity during gonadal differentiation. Bioch Biophys Acta 2002;1577:93-101.
60. Hossain A, Saunders GF. Role of Wilm's tumor 1 (WT1) in the transcriptional regulation of the Mullerian-inhibiting substance promoter. Biol Reprod 2003;69:1808-1814.
61. Suri M, Kelehan P, O'neill D, et al. WT1 mutations in Meacham syndrome suggest a coelomic mesothelial origin of the cardiac and diaphragmatic malformations. Am J Med Genet A 2007;143A:2312-2320.
62. Folch M, Pigem I, Konje JC. Mullerian agenesis: etiology, diagnosis and management. Obstet Gynecol Surv 2000;55: 644-649.
63. Deligeoroglou E, Kontoravdis A, Makrakis E, et al. Development of leiomyomas on the uterine remnant of two women with Mayer-Rokitansky-Kuster- Hauser syndrome. Fertil Steril 2004;81:1385-1387.
64. Deligeoroglou E, Christopoulos P, Creatsas G. A unique case of descending salpingitis and functioning endometrium in a Mullerian remnant in a woman with Mayer-Rokitansky-Kuster-Hauser syndrome. Fertil Steril 2005;83:1547-1548.
65. Tilker F, Yildirim SV, Barutcu O, et al. Familial mullerian agenesis. Turk J Pediatr 2000;42:322-324.
66. Strubbe EH, Cremers CW, Willemsen WN, et al. The Mayer-Rokitansky-Kuster- Hauser (MRKH) syndrome without and with associated features: two separate entities? Clin Dysmor-phol 1994;3:192-199.
67. Uliana V, Giordano N, Caselli R, et al. Expanding the pheno-type of 22q11 deletion syndrome: the MURCS association. Clin Dysmorphol 2008;17:13-17.
68. Brady AF, Winter RM, Wilson LC, et al. Hemifacial microso-mia, external auditory canal atresia, deafness and Mullerian anomalies associated with acroosteolysis: a new autosomal recessive syndrome? Clin Dysmorphol 2002;11:155-161.
69. Timmreck LS, Gray MR, Handelin B, et al. Analysis of cystic fibrosis transmembrane conductance regulator gene mutations in patients with congenital absence of the uterus and vagina. Am J Med Genet A 2003;120A:72-76.
70. Resendes BL, Sohn SH, Stelling JR, et al. Role for anti-Mullerian hormone in congenital absence of the uterus and vagina. Am J Med Genet 2001;98:129-136.
71. Klipstein S, Bhagavath B, Topicat C, et al. The N314D polymorphism of the GALT gene is not associated with congenital absence of the uterus and vagina. Mol Hum Reprod 2003;9: 171-174.
72. Zenteno JC, Carranza-Lira S, Kofman-Alfaro S. Molecular analysis of the anti-Mullerian hormone, the anti-Mullerian hormone receptor, and galactose-1-phosphate uridyl transferase genes in patients with the Mayer-Rokitansky-Kuster-Hauser syndrome. Arch Gynecol Obstet 2004;269:270-273.
73. Bingham C, Ellard S, Cole TR, et al. Solitary functioning kidney and diverse genital tract malformations associated with he-patocyte nuclear factor-1beta mutations. Kidney Int 2002;61: 1243-1251.
74. Biason-Lauber A, Konrad D, Navratil F, et al. A Wnt4 mutation associated with Mullerian-duct regression and virilization in a 46,XX woman. N Engl J Med 2004;351:792-798.
75. Clement-Ziza M, Khen N, Gonzales J, et al. Exclusion of Wnt4 as a major gene in Rokitansky-Kuster-Hauser anomaly. Am J Med Genet A 2005;137:98-99.
76. Jamin SP, Arango NA, Mishina Y, et al. Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nat Genet 2002;32:408-410.
77. Ravel C, Lorenço D, Dessolle L, et al. Mutational analysis of the WNT gene family in women with Mayer-Rokitansky-Kuster-Hauser syndrome. Fertil Steril 2009;91(suppl 4):1604-1607.
78. Burel A, Mouchel T, Odent S, et al. Role of Hoxa7 to Hoxa13 and PBX1 genes in various forms of MRKH syndrome (congenital absence of uterus and vagina). J Negat Results Biomed 2006;5:4.